A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

NCT05137054 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

317

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Linvoseltamab
DRUG: Daratumumab
DRUG: Carfilzomib
DRUG: Lenalidomide
DRUG: Bortezomib
DRUG: Pomalidomide
DRUG: Isatuximab
DRUG: Fianlimab
DRUG: Cemiplimab
DRUG: Nirogacestat
DRUG: Cevostamab

Sponsor

Regeneron Pharmaceuticals